Clinical Efficacy of Welpass®/ropivacaine after robotic urologic surgery: A randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0008822

Enrollment

110

Registered

2023-09-22

Start date

2023-09-11

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The Genewell product packaging consists of one syringe filled with gel, one syringe connector, and one empty syringe for filling ropivacaine (see diagram below). First, use the empty syringe to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 19 or older, but younger than 80, who have undergone robotic prostatectomy and robotic partial nephrectomy during the study period. Patients with sufficient activity to lead a normal daily life (Eastern Cooperative Oncology Group performance status of 0 or 1) Patients who can read and consent to the informed consent form.

Exclusion criteria

Exclusion criteria: Individuals allergic to analgesics Patients with severe hypertension Individuals who are pregnant Those who do not wish to voluntarily participate in the study Individuals deemed unsuitable for participation in the clinical trial at the discretion of the investigator

Design outcomes

Primary

Measure	Time frame
Amount of Fentanyl used through PCA within 72 hours after surgery	—

Secondary

Measure	Time frame
Amount of pain control medication used within 72 hours after surgery;NRS pain assessment at 6, 24, 48, and 72 hours after surgery	—

Countries

Korea, Republic of

Contacts

Public ContactBumjin Lim

Asan Medical Center

lbj1986@hanmail.net+82-2-3010-5892

Outcome results